1. Repositorio Institucional Universidad de Antioquia
  2. Investigaciones
  3. CIEN (Centro de Investigaciones en Ciencias Exactas y Naturales)
  4. Artículos de Revista en Ciencias Exactas y Naturales
Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/20366
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorSyro Moreno, Luis Vicente-
dc.contributor.authorRotondo, Fabio-
dc.contributor.authorCamargo Guerrero, Mauricio-
dc.contributor.authorOrtíz Gómez, León Darío-
dc.contributor.authorSerna Ortíz, Carlos Andrés-
dc.contributor.authorKovacs, Kalman-
dc.date.accessioned2021-06-25T01:51:12Z-
dc.date.available2021-06-25T01:51:12Z-
dc.date.issued2018-
dc.identifier.urihttp://hdl.handle.net/10495/20366-
dc.description.abstractABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.spa
dc.format.extent14spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherFrontiers Mediaspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/co/*
dc.titleTemozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directionsspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGenética Regeneración y Cáncerspa
dc.identifier.doi10.3389/fendo.2018.00318-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1664-2392-
oaire.citationtitleFrontiers in Endocrinologyspa
oaire.citationstartpage1spa
oaire.citationendpage14spa
oaire.citationvolume9spa
oaire.citationissue1spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by/4.0/spa
dc.publisher.placeLausana, Suizaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTREVspa
dc.type.localArtículo de revisiónspa
dc.subject.decsAgentes alquilantes-
dc.subject.decsAlkylating Agents-
dc.subject.decsAntineoplastic Agents-
dc.subject.decsAntineoplásicos-
dc.subject.decsReparación del ADN-
dc.subject.decsDNA Repair-
dc.subject.decsNeoplasias-
dc.subject.decsNeoplasms-
dc.subject.decsTumores Neuroendocrinos-
dc.subject.decsNeuroendocrine Tumors-
dc.subject.decsO(6)-Methylguanine-DNA Methyltransferase-
dc.subject.decsO(6)-Metilguanina-ADN Metiltransferasa-
dc.subject.decsNeoplasias Hipofisarias-
dc.subject.decsPituitary Neoplasms-
dc.subject.decsTemozolomida-
dc.subject.decsTemozolomide-
dc.subject.decsMetiltransferasa-
dc.subject.decsMethyltransferases-
dc.subject.lembQuimioterapia-
dc.subject.lembChemotherapy-
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fendo.2018.00318/fullspa
dc.description.researchgroupidCOL0006769spa
dc.relation.ispartofjournalabbrevFront. Endocrinol.spa
Aparece en las colecciones: Artículos de Revista en Ciencias Exactas y Naturales

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
CamargoMauricio_2018_TomozolomidePituitaryTumors.pdfArtículo de revisión1.54 MBAdobe PDFVisualizar/Abrir
Mostrar el registro sencillo del ítem


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons